Page last updated: 2024-11-05

1,2,6-hexanetriol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,2,6-hexanetriol is a triol, a molecule with three hydroxyl groups. It is a colorless, viscous liquid that is soluble in water and ethanol. It is used as a plasticizer, a humectant, and a viscosity modifier. 1,2,6-hexanetriol is also studied for its potential medicinal properties, as it has been shown to have antioxidant, anti-inflammatory, and antimicrobial activity. It is often used as a starting material for the synthesis of other organic compounds. The synthesis of 1,2,6-hexanetriol can be achieved through different methods, including the reaction of 1,2-epoxyhexane with water and the reduction of 1,2,6-hexanetrione. 1,2,6-hexanetriol is a relatively safe compound, with low toxicity and good biodegradability. '

1,2,6-hexanetriol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7823
CHEMBL ID3184716
CHEBI ID179443
SCHEMBL ID35437
MeSH IDM0350374

Synonyms (48)

Synonym
AKOS009031408
CHEBI:179443
ai3-14311
hexanetriol-1,2,6
brn 1304479
nsc 404957
einecs 203-424-6
1,2,6-trihydroxyhexane
hexane-1,2,6-triol
1,2,6-hexanetriol
nsc-404957
nsc404957
wln: q4yq & 1q
hexanetriol-1,6
1,6-trihydroxyhexane
hexane-1,6-triol
1,6-hexanetriol
106-69-4
1,2,6-trihydroxyhexane, >=95%
1,2,6-hexanetriol, 96%
H0104
NCGC00248249-01
dtxcid8021224
cas-106-69-4
dtxsid0041224 ,
tox21_300999
NCGC00254901-01
C20334
4-01-00-02784 (beilstein handbook reference)
unii-w45xxm0xwe
w45xxm0xwe ,
FT-0606267
1,2,6-hexanetriol [ii]
1,2,6-hexantriol
1,2,6-hexanetriol [inci]
H1069
SCHEMBL35437
Q-200059
hexanetriol-(1,2,6)
CHEMBL3184716
mfcd00002976
112254-74-7
Q18018076
AS-56858
SB83850
CS-W013379
EN300-19334
SY039672
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aliphatic alcoholAn alcohol derived from an aliphatic compound.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency64.90960.000714.592883.7951AID1259369
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency16.30450.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency14.36150.000817.505159.3239AID1159527; AID1159531
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.65280.000229.305416,493.5996AID743075
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency51.55950.001723.839378.1014AID743083
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's1 (10.00)18.2507
2000's1 (10.00)29.6817
2010's6 (60.00)24.3611
2020's1 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.38

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.38 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.99 (4.65)
Search Engine Demand Index31.58 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.38)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (10.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]